Fig. 5
From: Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
Meso-H.28z T cells exhibit enhanced antitumor capacities in vivo. a Timeline of events of the xenograft experiment with the subcutaneous inoculation of A549-GL cells. On day 0, 5 × 105 A549-GL cells were injected subcutaneously into the NSI mice, and on day 7 and day 10, 1 × 106 and 6 × 105 GFP T, Meso.28z T or Meso-H.28z T cells were injected through the tail vein into each mouse (n = 3). The cell numbers refer to transduced CAR T cells. b Tumor burden of mice treated with GFP T, Meso.28z T, or Meso-H.28z T cells from day 16 to 49 after A549-GL cell inoculation. On day 49, the mice were sacrificed and the tumors were analyzed. c–d Size and weight of subcutaneous A549-GL tumors from NSI mice treated with GFP T, Meso.28z T, or Meso-H.28z T cells on day 49 post-inoculation of A549-GL cells. Error bars denote the s.e.m. and the groups were compared through an unpaired t test. *P < 0.05, **P < 0.01, and ***P < 0.001